GEIF Ventures
VC Fund
Cambridge, United Kingdom
GEIF Ventures is a VC fund in Cambridge focused on Software and Health Care. GEIF Ventures Early Growth Fund is a £5 million co-investment fund within IQ Capital Partners established with the commitment by the Small Business Service to co-invest into promising early growth businesses with business angels who are members of Great Eastern Investment Forum (GEIF).GEIF Ventures helps angels to amplify their investing power,allowing them to spread their capital and management skills to a greater number of companies and ensure that such companies have sufficient funds to achieve profitability or the next key milestone.Combined with business angels’ finance, GEIFV investment will help to bridge the equity gap faced by many early stage companies.
- Total investments:
- 9
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries GEIF Ventures invests in
Stages GEIF Ventures invests in
Countries GEIF Ventures invests in
Round sizes
Round size
- Seed
- $2.5M–$2.6M
Investment Focus
Industry
- Software 3 (33%)
- Health Care 3 (33%)
- Internet 2 (22%)
- Biotechnology 2 (22%)
- Financial Services 2 (22%)
Stage
- Funding Round 4 (44%)
- Seed 3 (33%)
- Series A 1 (11%)
- Venture - Series Unknown 1 (11%)
Country
- United Kingdom 8 (89%)
- United States 1 (11%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Funderbeam is a funding and trading platform that connects companies and investors to buy and sell equity stakes. The platform allows the founders to gain exposure, legal support, a funding manager, or an investor network. It also allows the investors to take control of their investments and trade anytime they want.The company was founded in 2013as a global data platform for startup companies. | $2.6M / Seed / Oct 12, 2016 | ||
| Desktop Genetics is an international biotechnology company established in 2012 to help researchers discover and treat the root genetic causes of human disease. Today, Desktop Genetics is a recognised leader in genome editing technology, staffed by dedicated team of genome editing experts, bioinformaticians and data scientists, driven by thereal-world impact of CRISPR technology.They have invested four years developing their core technology, DESKGEN AI, trained on the largest database of genome editing data in the world. DESKGEN AI powers their flagship DESKGEN CRISPR Library product range, which enables the work of their pharma, biotech and academic customers working in drug discovery and functional genomics. Desktop Genetics' tools and technologies are used by over 1800 organisations all over the world, and their projects contribute directly to several key partnerships to bring CRISPR into the clinic. The company has received awards from Fast Company, Kairos 50 and SxSW Interactive. | $2.1M / Venture - Series Unknown / Sep 15, 2015 | ||
| BioBeats is a human company that creates digital artificial intelligence products to tackle mental health globally. Mental and substance use disorders constitute 10.4% of the global burden of disease and are the leading cause of disability among all disease groups. The global direct and indirect economic costs of mental disorders were estimated atUS$2.5 trillion in 2010, and are growing. Both direct and indirect costs of mental disorders are expected to double by 2030.Current clinical and social provisions are inadequate and rely on therapeutic devices that cannot track neurological and physiological correlates to psychological progress. Smartphones and wearables brought real-time data. BioBeats is the result of 15 years of research, 5 of which have been in commercial/clinical/consumer deployment. Their team fuses work at the Institute of Biomedical Engineering and the Social Cognition Lab at the University of Oxford to use real-time data not only to bring physiological data to psychological therapy but to produce machine learning that can predict the onset of the disorder and intervene early.BioBeats was established in 2012 and is based in London, England, United Kingdom. | Seed / Feb 01, 2015 | ||
| Grapeshot (Acquired by Oracle) empowers the world’s leading brands and advertisers to bring relevance to every customer experience. With its proprietary Contextual Intelligence platform, Grapeshot transforms information into actionable data, and identifies revenue-driving behaviors.With solutions for predictive targeting, brand safety, andaudience enrichment, advertisers, media agencies, programmatic platforms and publishers use power of Grapeshot to improve media efficiency, increase customer engagement and boost brand perception with their intended audiences.It has been named “Digiday’s Best Publisher Tool” and “Best Attribution Solution for Keyword Signal,” The Drum’s “Best Attribution Solution,” and the British Media Awards’ “Ad Provider of the Year,” among other honors.Grapeshot entered the market in 2006, and has offices in San Francisco, Los Angeles, Chicago, Toronto, New York, London, Cambridge, Singapore, Hong Kong, Shanghai and Sydney. | $3.3M / Mar 28, 2014 | ||
| Atto takes the lead with a clear mission, to shape a more predictable future for lenders. Using real-time bank transaction data, Atto delivers a suite of predictive models to empower risk management.Atto offers a range of insights that gives risk managers a detailed view of customer spending, saving, and earning. This added level of understandingenhances credit risk assessment and promotes a more compliant lending environment.Providing accurate foresight lies at the heart of Atto's values. By leveraging current financial information, consumers are more likely to receive equitable treatment, whilst businesses gain the tools to make more informed and appropriate lending decisions.With innovation in data science at its core, Atto paves the way for a future where complex decisions can be made in real-time with impossibly recent data. | $2.5M / Seed / Apr 30, 2012 | ||
| The creative appilcation of data, analyis and technoloyg to underpin public sector procurement transformation. Spikes Cavell – a leading light in spend management. Spikes Cavell is a leader in data-based solutions. Their extensive expertise was built up through developing innovative data-based solutions to support decision making andprogramme execution in the private sector. Since 2004, Spikes Cavell have turned their attention to translating this experience into producing solutions to help public sector organisations transform their procurement. Their years of experience, combined with their track record in delivering on their promises, have helped them become the leading supplier of spend management solutions to the public sector. Spikes Cavell customers include organisations from all areas of the public sector, nationwide and number over 600.Spikes Cavell & Co. was founded in 1991 and is based in Newbury, United Kingdom. | $2.6M / Series A / Nov 17, 2009 | ||
| Leveraging the extensive knowledge of GSK's Biotransformation and Natural Products scientific team, Novacta Biosystems Ltd was founded in 2003. In the following 5 years, Novacta successfully adopted a dual business model, whereby it developed a biocatalysis and microbial pathway engineering service business, that supported its efforts to buildan infectious disease therapeutic pipeline. | $658K / Aug 07, 2007 | ||
| Chameleon BioSurfaces is a provider of sophisticated surface design technology to medical device companies. Chameleon works closely with its customers to design and produce unique solutions to specific device challenges and opportunities. | $938K / Oct 19, 2006 | ||
| Camrivox Ltd offers customers simple and effective Telephony Integration with CRM. The company has pioneered the development and delivery of Flexor Software, greatly simplifying CRM Telephony Integration that has traditionally relied upon large investments in infrastructure, hardware and support staff. With Flexor Software uniquely delivered andsupported at the PC level, companies can bypass this resource-laden route, improving business processes and increasing customer satisfaction. Camrivox, founded in 2005, is headquartered in Cambridge, UK. | $1.6M / Mar 07, 2006 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does GEIF Ventures invest in?
GEIF Ventures invests primarily in Software, Health Care and Internet startups, most often at Funding Round and Seed stage. Most of the 9 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does GEIF Ventures invest in?
GEIF Ventures typically joins rounds of $2.5M–$2.6M at Seed. These are whole funding-round sizes, not GEIF Ventures's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds GEIF Ventures took part in.
When did GEIF Ventures last invest?
The most recent investment recorded for GEIF Ventures closed in Oct 2016. Shizune tracks 9 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
